1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Perceptive Advisors Llc Buys Iovance Biotherapeutics Inc, Zymeworks Inc, Regeneron Pharmaceuticals Inc, Sells Amarin Corp PLC, Momenta Pharmaceuticals Inc, Foamix Pharmaceuticals

New York, NY, based Investment company Perceptive Advisors Llc (Current Portfolio) buys Iovance Biotherapeutics Inc, Zymeworks Inc, Regeneron Pharmaceuticals Inc, Nevro Corp, Allogene Therapeutics Inc, sells Amarin Corp PLC, Momenta Pharmaceuticals Inc, Foamix Pharmaceuticals, Bio-Rad Laboratories Inc, eHealth Inc during the 3-months ended 2020Q1, according to the most recent filings of the investment company, Perceptive Advisors Llc. As of 2020Q1, Perceptive Advisors Llc owns 99 stocks with a total value of $3.7 billion. These are the details of the buys and sells.

For the details of PERCEPTIVE ADVISORS LLC's stock buys and sells, go to https://www.gurufocus.com/guru/perceptive+advisors+llc/current-portfolio/portfolio

These are the top 5 holdings of PERCEPTIVE ADVISORS LLC
  1. Iovance Biotherapeutics Inc (IOVA) - 11,670,057 shares, 9.54% of the total portfolio. Shares added by 23.94%
  2. Global Blood Therapeutics Inc (GBT) - 6,065,726 shares, 8.47% of the total portfolio. Shares added by 3.41%
  3. Neurocrine Biosciences Inc (NBIX) - 3,063,263 shares, 7.24% of the total portfolio. Shares reduced by 15.21%
  4. Mirati Therapeutics Inc (MRTX) - 3,319,450 shares, 6.97% of the total portfolio. Shares added by 3.62%
  5. Amicus Therapeutics Inc (FOLD) - 25,182,364 shares, 6.36% of the total portfolio. Shares added by 0.20%
New Purchase: Regeneron Pharmaceuticals Inc (REGN)

Perceptive Advisors Llc initiated holding in Regeneron Pharmaceuticals Inc. The purchase prices were between $336.18 and $494.43, with an estimated average price of $411.31. The stock is now traded at around $566.33. The impact to a portfolio due to this purchase was 1.07%. The holding were 80,000 shares as of .

New Purchase: Allogene Therapeutics Inc (ALLO)

Perceptive Advisors Llc initiated holding in Allogene Therapeutics Inc. The purchase prices were between $18.22 and $28.25, with an estimated average price of $23.87. The stock is now traded at around $45.29. The impact to a portfolio due to this purchase was 0.82%. The holding were 1,543,790 shares as of .

New Purchase: Theravance Biopharma Inc (TBPH)

Perceptive Advisors Llc initiated holding in Theravance Biopharma Inc. The purchase prices were between $17.84 and $31.21, with an estimated average price of $25.05. The stock is now traded at around $27.50. The impact to a portfolio due to this purchase was 0.63%. The holding were 1,000,000 shares as of .

New Purchase: Menlo Therapeutics Inc (MNLO)

Perceptive Advisors Llc initiated holding in Menlo Therapeutics Inc. The purchase prices were between $2.18 and $6.94, with an estimated average price of $4.41. The stock is now traded at around $1.70. The impact to a portfolio due to this purchase was 0.48%. The holding were 6,637,179 shares as of .

New Purchase: Denali Therapeutics Inc (DNLI)

Perceptive Advisors Llc initiated holding in Denali Therapeutics Inc. The purchase prices were between $14.2 and $27.98, with an estimated average price of $20.9. The stock is now traded at around $23.89. The impact to a portfolio due to this purchase was 0.41%. The holding were 850,000 shares as of .

New Purchase: Insulet Corp (PODD)

Perceptive Advisors Llc initiated holding in Insulet Corp. The purchase prices were between $130.01 and $216.44, with an estimated average price of $183.11. The stock is now traded at around $200.94. The impact to a portfolio due to this purchase was 0.37%. The holding were 82,733 shares as of .

Added: Iovance Biotherapeutics Inc (IOVA)

Perceptive Advisors Llc added to a holding in Iovance Biotherapeutics Inc by 23.94%. The purchase prices were between $19.54 and $38.85, with an estimated average price of $26.44. The stock is now traded at around $35.74. The impact to a portfolio due to this purchase was 1.84%. The holding were 11,670,057 shares as of .

Added: Zymeworks Inc (ZYME)

Perceptive Advisors Llc added to a holding in Zymeworks Inc by 48.19%. The purchase prices were between $24.28 and $49.8, with an estimated average price of $41.23. The stock is now traded at around $37.16. The impact to a portfolio due to this purchase was 1.12%. The holding were 3,560,999 shares as of .

Added: Nevro Corp (NVRO)

Perceptive Advisors Llc added to a holding in Nevro Corp by 42.96%. The purchase prices were between $70.23 and $144.31, with an estimated average price of $120.56. The stock is now traded at around $122.82. The impact to a portfolio due to this purchase was 0.88%. The holding were 1,092,068 shares as of .

Added: Collegium Pharmaceutical Inc (COLL)

Perceptive Advisors Llc added to a holding in Collegium Pharmaceutical Inc by 268.34%. The purchase prices were between $13.89 and $25.45, with an estimated average price of $20.72. The stock is now traded at around $23.75. The impact to a portfolio due to this purchase was 0.5%. The holding were 1,551,722 shares as of .

Added: ADMA Biologics Inc (ADMA)

Perceptive Advisors Llc added to a holding in ADMA Biologics Inc by 43.95%. The purchase prices were between $1.5 and $4.59, with an estimated average price of $3.48. The stock is now traded at around $2.63. The impact to a portfolio due to this purchase was 0.4%. The holding were 16,584,802 shares as of .

Added: DBV Technologies SA (DBVT)

Perceptive Advisors Llc added to a holding in DBV Technologies SA by 67.54%. The purchase prices were between $2.33 and $12.98, with an estimated average price of $9.06. The stock is now traded at around $5.37. The impact to a portfolio due to this purchase was 0.31%. The holding were 7,317,809 shares as of .

Sold Out: Amarin Corp PLC (AMRN)

Perceptive Advisors Llc sold out a holding in Amarin Corp PLC. The sale prices were between $4 and $21.53, with an estimated average price of $16.75.

Sold Out: Foamix Pharmaceuticals Ltd (FOMX)

Perceptive Advisors Llc sold out a holding in Foamix Pharmaceuticals Ltd. The sale prices were between $2.99 and $4.71, with an estimated average price of $3.99.

Sold Out: eHealth Inc (EHTH)

Perceptive Advisors Llc sold out a holding in eHealth Inc. The sale prices were between $85.7 and $146.09, with an estimated average price of $114.23.

Sold Out: Tandem Diabetes Care Inc (TNDM)

Perceptive Advisors Llc sold out a holding in Tandem Diabetes Care Inc. The sale prices were between $47.37 and $90.04, with an estimated average price of $70.13.

Sold Out: Arvinas Inc (ARVN)

Perceptive Advisors Llc sold out a holding in Arvinas Inc. The sale prices were between $33 and $54.5, with an estimated average price of $46.8.

Sold Out: Aurinia Pharmaceuticals Inc (AUPH)

Perceptive Advisors Llc sold out a holding in Aurinia Pharmaceuticals Inc. The sale prices were between $11.34 and $21.46, with an estimated average price of $17.73.

Reduced: Momenta Pharmaceuticals Inc (MNTA)

Perceptive Advisors Llc reduced to a holding in Momenta Pharmaceuticals Inc by 98.92%. The sale prices were between $18.96 and $33.96, with an estimated average price of $27.82. The stock is now traded at around $31.49. The impact to a portfolio due to this sale was -1.14%. Perceptive Advisors Llc still held 30,637 shares as of .

Reduced: Bio-Rad Laboratories Inc (BIO)

Perceptive Advisors Llc reduced to a holding in Bio-Rad Laboratories Inc by 94.91%. The sale prices were between $320.01 and $409.07, with an estimated average price of $368.41. The stock is now traded at around $471.35. The impact to a portfolio due to this sale was -0.49%. Perceptive Advisors Llc still held 3,489 shares as of .

Reduced: Arena Pharmaceuticals Inc (ARNA)

Perceptive Advisors Llc reduced to a holding in Arena Pharmaceuticals Inc by 29.17%. The sale prices were between $34.83 and $54.15, with an estimated average price of $45.98. The stock is now traded at around $53.19. The impact to a portfolio due to this sale was -0.26%. Perceptive Advisors Llc still held 675,129 shares as of .

Reduced: AnaptysBio Inc (ANAB)

Perceptive Advisors Llc reduced to a holding in AnaptysBio Inc by 50%. The sale prices were between $12.82 and $18.69, with an estimated average price of $15.2. The stock is now traded at around $19.87. The impact to a portfolio due to this sale was -0.17%. Perceptive Advisors Llc still held 500,000 shares as of .

Reduced: Turning Point Therapeutics Inc (TPTX)

Perceptive Advisors Llc reduced to a holding in Turning Point Therapeutics Inc by 20.01%. The sale prices were between $32.02 and $66.17, with an estimated average price of $53.48. The stock is now traded at around $64.70. The impact to a portfolio due to this sale was -0.11%. Perceptive Advisors Llc still held 349,890 shares as of .



Here is the complete portfolio of PERCEPTIVE ADVISORS LLC. Also check out:

1. PERCEPTIVE ADVISORS LLC's Undervalued Stocks
2. PERCEPTIVE ADVISORS LLC's Top Growth Companies, and
3. PERCEPTIVE ADVISORS LLC's High Yield stocks
4. Stocks that PERCEPTIVE ADVISORS LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)